Abstract
Adriamycin, a new antitumor antibiotic of the anthracycline group with a structural formula very similar to daunomycin, was tested for antitumor activity against ascitic and solid tumors. Its antitumor activity was compared to that of daunomycin, mitomycin C and endoxan. A strong inhibiting effect is exerted by adriamycin on the growth of EHRLICH ascites carcinoma, ascitic Saroma-180, Hepatoma MH-134, Lymphoma 6 C3HED·OG, Leukemia L-1210 and solid Sarcoma-180. The survival time of treated animals is considerably increased. However, the growth of solid YOSHIDA sarcoma was weakly inhibited.
